PL4284511T3 - Azachinoliny jako inhibitory cd38 - Google Patents
Azachinoliny jako inhibitory cd38Info
- Publication number
- PL4284511T3 PL4284511T3 PL22704226.4T PL22704226T PL4284511T3 PL 4284511 T3 PL4284511 T3 PL 4284511T3 PL 22704226 T PL22704226 T PL 22704226T PL 4284511 T3 PL4284511 T3 PL 4284511T3
- Authority
- PL
- Poland
- Prior art keywords
- azaquinolines
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163143245P | 2021-01-29 | 2021-01-29 | |
| PCT/US2022/014221 WO2022165114A1 (en) | 2021-01-29 | 2022-01-28 | Quinolines and azaquinolines as inhibitors of cd38 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4284511T3 true PL4284511T3 (pl) | 2025-12-22 |
Family
ID=80446310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22704226.4T PL4284511T3 (pl) | 2021-01-29 | 2022-01-28 | Azachinoliny jako inhibitory cd38 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11952377B2 (pl) |
| EP (2) | EP4674415A3 (pl) |
| JP (2) | JP7777596B2 (pl) |
| KR (1) | KR20230141799A (pl) |
| CN (1) | CN117580829A (pl) |
| AR (1) | AR124718A1 (pl) |
| AU (1) | AU2022212035A1 (pl) |
| BR (1) | BR112023014898A2 (pl) |
| CA (1) | CA3208851A1 (pl) |
| CL (2) | CL2023002163A1 (pl) |
| CO (1) | CO2023009803A2 (pl) |
| CR (1) | CR20230323A (pl) |
| DO (1) | DOP2023000142A (pl) |
| EC (1) | ECSP23056223A (pl) |
| ES (1) | ES3042412T3 (pl) |
| HR (1) | HRP20251111T1 (pl) |
| HU (1) | HUE072981T2 (pl) |
| IL (1) | IL304466A (pl) |
| JO (1) | JOP20230160A1 (pl) |
| MX (1) | MX2023008701A (pl) |
| PE (1) | PE20232047A1 (pl) |
| PL (1) | PL4284511T3 (pl) |
| RS (1) | RS67253B1 (pl) |
| TW (1) | TW202241418A (pl) |
| WO (1) | WO2022165114A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11535621B2 (en) | 2019-07-31 | 2022-12-27 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of CD38 |
| EP4263524A1 (en) | 2020-12-21 | 2023-10-25 | Cytokinetics, Inc. | Pyrazole derivatives useful as nampt modulators |
| CN117715897A (zh) | 2021-04-30 | 2024-03-15 | 南京艾美斐生物医药科技有限公司 | 化合物及其作为cd38抑制剂的用途 |
| WO2024217995A1 (en) | 2023-04-20 | 2024-10-24 | Syngenta Crop Protection Ag | Pesticidally active dihydropyridinone derivatives |
| WO2026000074A1 (en) * | 2024-06-25 | 2026-01-02 | Welnx Company Inc. | Use of cd38 inhibitors for reducing th2 inflammation |
| WO2026075971A1 (en) | 2024-10-01 | 2026-04-09 | Neolaia Inc. | Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors |
| WO2026143058A1 (en) * | 2024-12-23 | 2026-07-02 | Neolaia Inc. | Pyridopyrimidine compounds useful as cd38 inhibitors |
| WO2026143049A1 (en) * | 2024-12-23 | 2026-07-02 | Neolaia Inc. | Aminoquinolinones useful as cd38 inhibitors |
| CN119775288B (zh) * | 2024-12-31 | 2025-10-10 | 浙江工业大学 | 一种cd38抑制化合物及应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2646020B1 (en) | 2010-12-01 | 2016-09-21 | Glaxosmithkline LLC | Indoles |
| AU2012332297B2 (en) | 2011-11-04 | 2016-01-07 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treatment |
| EA201591746A1 (ru) | 2013-03-14 | 2016-08-31 | КОНВЕРДЖЕН ЭлЭлСи | Способы и композиции для ингибирования бромодомен-содержащих белков |
| CN107428733A (zh) | 2014-12-03 | 2017-12-01 | 葛兰素史克知识产权第二有限公司 | Cd38抑制剂和治疗方法 |
| WO2017053604A1 (en) | 2015-09-23 | 2017-03-30 | The Regents Of The University Of California | Potent antiviral pyrazolopyridine compounds |
| WO2018151830A1 (en) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
| EP3434692A1 (en) | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
| US11535621B2 (en) | 2019-07-31 | 2022-12-27 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of CD38 |
| US20230025807A1 (en) | 2019-10-30 | 2023-01-26 | Mitobridge Inc. | Cd38 inhibitors |
| KR20230051425A (ko) | 2020-04-07 | 2023-04-18 | 미토브리지, 인크. | Cd38 억제제 |
-
2022
- 2022-01-28 AR ARP220100173A patent/AR124718A1/es unknown
- 2022-01-28 HR HRP20251111TT patent/HRP20251111T1/hr unknown
- 2022-01-28 PE PE2023002190A patent/PE20232047A1/es unknown
- 2022-01-28 CN CN202280022060.6A patent/CN117580829A/zh active Pending
- 2022-01-28 BR BR112023014898A patent/BR112023014898A2/pt unknown
- 2022-01-28 AU AU2022212035A patent/AU2022212035A1/en active Pending
- 2022-01-28 PL PL22704226.4T patent/PL4284511T3/pl unknown
- 2022-01-28 EP EP25188747.7A patent/EP4674415A3/en active Pending
- 2022-01-28 HU HUE22704226A patent/HUE072981T2/hu unknown
- 2022-01-28 KR KR1020237027359A patent/KR20230141799A/ko not_active Withdrawn
- 2022-01-28 CR CR20230323A patent/CR20230323A/es unknown
- 2022-01-28 JP JP2023544674A patent/JP7777596B2/ja active Active
- 2022-01-28 US US17/586,939 patent/US11952377B2/en active Active
- 2022-01-28 WO PCT/US2022/014221 patent/WO2022165114A1/en not_active Ceased
- 2022-01-28 CA CA3208851A patent/CA3208851A1/en active Pending
- 2022-01-28 TW TW111103880A patent/TW202241418A/zh unknown
- 2022-01-28 RS RS20250955A patent/RS67253B1/sr unknown
- 2022-01-28 EP EP22704226.4A patent/EP4284511B1/en active Active
- 2022-01-28 MX MX2023008701A patent/MX2023008701A/es unknown
- 2022-01-28 ES ES22704226T patent/ES3042412T3/es active Active
-
2023
- 2023-07-13 IL IL304466A patent/IL304466A/en unknown
- 2023-07-20 JO JOJO/P/2023/0160A patent/JOP20230160A1/ar unknown
- 2023-07-24 CL CL2023002163A patent/CL2023002163A1/es unknown
- 2023-07-25 DO DO2023000142A patent/DOP2023000142A/es unknown
- 2023-07-25 EC ECSENADI202356223A patent/ECSP23056223A/es unknown
- 2023-07-25 CO CONC2023/0009803A patent/CO2023009803A2/es unknown
-
2024
- 2024-02-28 US US18/590,300 patent/US20240279224A1/en active Pending
- 2024-05-22 CL CL2024001535A patent/CL2024001535A1/es unknown
-
2025
- 2025-06-25 JP JP2025107301A patent/JP2025160175A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE072981T2 (hu) | Azakinolinok mint CD38 gátlók | |
| IL289878A (en) | Tricyclic amides as inhibitors of cd38 | |
| IL320739A (en) | rock2 inhibitors | |
| IL317736A (en) | Compounds as AXL inhibitors | |
| IL308476A (en) | Inhibitors of the menin-mil interaction | |
| ZA202106766B (en) | Compounds as inhibitors of macrophage migration inhibitory factor | |
| IL313548A (en) | MET kinase inhibitors | |
| HUE068818T2 (hu) | Transzglutamináz inhibitorok | |
| IL304159A (en) | A preparation containing bl-8040 | |
| IL316616A (en) | ROCK2 inhibitors | |
| GB202103774D0 (en) | Detectiion of Ransomware | |
| PL4192814T3 (pl) | Inhibitory transglutaminaz | |
| GB202411655D0 (en) | Application of circHIF1a | |
| SI4192812T1 (sl) | Zaviralci transglutaminaz | |
| IL288782B1 (en) | Sustained-release alpha-ketoglutarate preparations | |
| IL326324A (en) | Processes of preparing pi3k inhibitors | |
| ES3065110T3 (en) | Novel inhibitors of autotaxin | |
| EP4405346A4 (en) | SMALL MOLECULE INHIBITORS OF TEAD-YAP | |
| IL317047A (en) | Solid forms of heterocyclylamides as IRAK4 inhibitors | |
| IL291368A (en) | Inhibits expression of methadherin | |
| GB202107612D0 (en) | Inhibitors of metallo-beta-lactamases | |
| HK40075513A (en) | Heterobicyclic amides as inhibitors of cd38 | |
| GB202203181D0 (en) | Inhibitors of elF4A | |
| PT4192814T (pt) | Inibidores de transglutaminases | |
| GB202114327D0 (en) | Uses of terpenophenolic compounds |